All In Biotech

Investigational drug · Phase 3

VDPHL01

Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Androgenetic Alopecia, AGA, Male Pattern Baldness.

Phase 3

Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

4

4 still active

All registered trials

4

Any phase or sponsor naming "VDPHL01"

First trial start

2024

Jul 8, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "VDPHL01", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Androgenetic Alopecia
  • AGA
  • Male Pattern Baldness
  • Androgenetic Alopecia (AGA)
  • Female Androgenetic Alopecia
  • Hair Loss

Approved drugs for the same conditions: Immunology and inflammation

Largest trials

Live from ClinicalTrials.gov: studies naming "VDPHL01" as an intervention, largest first.

All trials
  • Veradermics, Inc.Industry

    NCT07146022 · 552 participants (planned) · Start Jul 25, 2025 · Primary completion Jun 2027

    Drug: VDPHL01 QD; Placebo and 2 more · For: Androgenetic Alopecia (AGA); Androgenetic Alopecia; AGA and 2 more

    Sites: Birmingham, Alabama; Phoenix, Arizona; Fort Smith, Arkansas · 71 sites in all

  • Efficacy and Safety of VDPHL01 in Males With AGAPivotal-lookingActive, not recruiting

    Veradermics, Inc.Industry

    NCT06724614 · 480 participants (planned) · Start Nov 6, 2024 · Primary completion Feb 2026

    Drug: VDPHL01; Placebo · For: Androgenetic Alopecia; AGA; Male Pattern Baldness

    Sites: Birmingham, Alabama; Phoenix, Arizona; Fort Smith, Arkansas · 44 sites in all

  • Safety and Efficacy of VDPHL01 in Males With AGAPivotal-lookingActive, not recruiting

    Veradermics, Inc.Industry

    NCT06972264 · 480 participants (planned) · Start Mar 11, 2025 · Primary completion Dec 2026

    Drug: VDPHL01; Placebo · For: Androgenetic Alopecia; AGA; Male Pattern Baldness

    Sites: Birmingham, Alabama; Phoenix, Arizona; Encino, California · 44 sites in all

  • Veradermics, Inc.Industry

    NCT06527365 · 70 participants (planned) · Start Jul 8, 2024 · Primary completion Aug 2026

    Drug: VDPHL01 · For: Androgenetic Alopecia; AGA; Male Pattern Baldness

    Sites: San Diego, California; New Albany, Indiana; Hackensack, New Jersey · 4 sites in all

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Androgenetic Alopecia

  • PP405 0.05%PP405Phase 33 trials

    Pelage Pharmaceuticals, Inc. · Androgenetic Alopecia

  • DA-001Phase 31 trial

    Applied Biology, Inc. · Telogen Effluvium, Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia

  • SecretomeConditioned, Umbilical Cord Mesenchymal Stem Cells derived ConditionedPhase 24 trials

    PT. Prodia Stem Cell Indonesia · Acute Respiratory Distress Syndrome, Androgenetic Alopecia, Ischemic Stroke

  • AD-3031Phase 21 trial

    Moogene Medi Co., Ltd · Androgenetic Alopecia

  • AD-303APhase 21 trial

    Moogene Medi Co., Ltd · Androgenetic Alopecia

  • EPI-001Phase 21 trial

    Epibiotech · Androgenetic Alopecia

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.